Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase I Pipeline Programs

First-in-human and early clinical safety studies in Phase I.

Programs 4,713
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 4,713 phase i pharmaceutical pipeline programs from ClinicalTrials.gov. First-in-human and early clinical safety studies in Phase I.

Top sponsors

Pipeline programs

Page 25 of 99

  1. CD19/BCMA in vivo CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Autoimmune Diseases

    phase 1 small molecule active

    1 trial

  2. CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells (UCAR-T) infusing

    The First People's Hospital of Lianyungang

    Refractory Idiopathic Membranous Nephropathy

    phase 1 small molecule active

    1 trial

  3. CD19/CD20 Dual-CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Non-Hodgkin's Lymphoma

    phase 1 mab on hold

    1 trial

  4. CD19/CD20 Dual-CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Leukemia

    phase 1 mab completed

    1 trial

  5. CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product

    Nanjing Legend Biotech Co.

    Relapsed/Refractory B-cell Malignancies

    phase 1 mab active

    1 trial

  6. CD56-Enriched Donor Lymphocyte Infusion

    Teva Pharma GmbH

    Multiple Myeloma

    phase 1 mab completed

    1 trial

  7. CD5CAR-NK cells for refractory invasive mold disease

    The George Institute

    refractory invasive mold disease

    phase 1 other active

    1 trial

  8. CD7 UCAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    T-cell Leukemia

    phase 1 mab active

    1 trial

  9. CD70 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Metastatic Tumor

    phase 1 mab active

    4 trials

  10. CD70 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Renal Cell Carcinoma

    phase 1 mab active

    1 trial

  11. CD70 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Ovarian Cancer

    phase 1 mab active

    1 trial

  12. CD70-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Renal Cell Carcinoma (RCC)

    phase 1 mab active

    1 trial

  13. CDAK539A12102

    Novartis Pharmaceuticals

    Patients with advanced malignancies

    phase 1 other active

    1 trial

  14. CDAK539A12103

    Novartis Pharmaceuticals

    Advanced Malignancies and Hepatic Impairment

    phase 1 other active

    1 trial

  15. CDD-2101

    BRIGHT MINDS BIOSCIENCES INC.

    Constipation - Functional

    phase 1 small molecule completed

    1 trial

  16. CDFF332A12101

    Novartis Pharmaceuticals

    Advanced, relapsed Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  17. CDKY709A12101C

    Novartis Pharmaceuticals

    Nasopharyngeal Carcinoma, Triple Negative Breast Cancer, Microsatellite Stable Colorectal Cancer, Non-Small Cell Lung Cancer, Cutaneous Melanoma

    phase 1 other active

    1 trial

  18. CDLX313A12101

    Novartis Pharmaceuticals

    Parkinson’s Disease

    phase 1 other active

    1 trial

  19. CE marked Philips Motiva system

    United Therapeutics Europe Ltd

    COPD

    phase 1 other completed

    1 trial

  20. CEA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Colorectal Cancer

    phase 1 mab active

    1 trial

  21. CEA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Gastric Cancer

    phase 1 mab active

    1 trial

  22. CEA protein antigen plus BCG Vaccine Mix for percutaneous use

    Lxo Ireland Designated Activity Company

    Rectal Cancer

    phase 1 mab active

    1 trial

  23. CEA-targeted CAR-T (Intravenous)

    Chongqing Precision Biotech Co., Ltd

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 1 mab active

    1 trial

  24. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Colorectal Cancer

    phase 1 mab active

    1 trial

  25. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Peritoneal Metastases From Colorectal Cancer

    phase 1 mab active

    1 trial

  26. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Lung Cancer

    phase 1 mab active

    1 trial

  27. CEC-012/BIO

    Dr. Falk Pharma GmbH

    No medical condition.

    phase 1 other active

    1 trial

  28. CEGF816X2102

    Novartis Pharmaceuticals

    Patients with EGFR-mutant Non Small Cell Lung Cancer

    phase 1 other active

    1 trial

  29. CEND-1

    LISATA THERAPEUTICS, INC.

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  30. CEP-11981 (kinase inhibitor)

    Teva Pharma GmbH

    Cancer

    phase 1 small molecule completed

    1 trial

  31. CEP-26401

    Teva Pharma GmbH

    Cognitive Impairment

    phase 1 small molecule completed

    1 trial

  32. CEP-37250/KHK2804

    Teva Pharma GmbH

    Solid Tumour

    phase 1 small molecule completed

    1 trial

  33. CEP-37251

    Teva Pharma GmbH

    Bone Loss

    phase 1 small molecule terminated

    1 trial

  34. CEP-37440

    Teva Pharma GmbH

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  35. CEP-9722

    Teva Pharma GmbH

    Solid Tumor

    phase 1 small molecule completed

    1 trial

  36. CEP-9722

    Teva Pharma GmbH

    Solid Tumors or Mantle Cell Lymphoma

    phase 1 small molecule completed

    1 trial

  37. CER-1236

    CERO THERAPEUTICS HOLDINGS, INC.

    AML

    phase 1 small molecule active

    1 trial

  38. CERC-006

    Avalo Therapeutics

    Lymphatic Malformation

    phase 1 small molecule terminated

    1 trial

  39. CERE-110: Adeno-Associated Virus Delivery of NGF

    SANGAMO THERAPEUTICS, INC

    Alzheimer's Disease

    phase 1 gene therapy completed

    1 trial

  40. CERE-120: AAV2-NTN

    SANGAMO THERAPEUTICS, INC

    Parkinson's Disease

    phase 1 gene therapy completed

    1 trial

  41. CEREAL-IPC 2016-010

    The George Institute

    Acute leukemia and myelodysplastic syndromes

    phase 1 other active

    1 trial

  42. CFA-1028-2-23

    Laboratorios Tillomed Spain S.L.U

    No medical condition.

    phase 1 other active

    1 trial

  43. CFA-1034-1-23

    Laboratorios Tillomed Spain S.L.U

    No medical condition

    phase 1 other active

    1 trial

  44. CFA-1034-2-23

    Laboratorios Tillomed Spain S.L.U

    No medical condition.

    phase 1 other active

    1 trial

  45. CFA-1037-1-24

    Laboratorios Tillomed Spain S.L.U

    No medical condition.

    phase 1 other active

    1 trial

  46. CFA-1042-1-24

    Laboratorios Tillomed Spain S.L.U

    No medical condition

    phase 1 other active

    1 trial

  47. CFA-1042-3-26

    Laboratorios Tillomed Spain S.L.U

    No medical condition

    phase 1 other active

    1 trial

  48. CFA-1048-1-25

    Laboratorios Tillomed Spain S.L.U

    No medical condition.

    phase 1 other active

    1 trial

Frequently asked questions

How many Phase I pipeline programs are in the directory?

4,713 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.